AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$27.17
−$0.21 (−0.75%) 1:00 PM ET
Prev closePrevC$27.37
OpenOpen$28.34
Day highHigh$28.34
Day lowLow$26.94
VolumeVol200,268
Avg volAvgVol296,906
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.59B
Sector
Healthcare
AI report sections
MIXED
OCS
Oculis Holding AG
Oculis shows firm upward price momentum over 3–12 months with the latest close near the upper end of its 52-week range and above key moving averages. Technical indicators highlight multiple bullish breakout and momentum signals but also flag an overbought RSI that may indicate near-term exhaustion risk. The balance sheet appears equity-heavy with ample current assets relative to current liabilities while short interest remains very low despite an elevated short-volume ratio in recent trading.
AI summarized at 6:27 PM ET, 2025-12-06
AI summary scores
INTRADAY:68SWING:72LONG:60
Volume vs average
Intraday (cumulative)
+101% (Above avg)
Vol/Avg: 2.01×
RSI
55.30(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: -0.00 Signal: -0.00
Short-Term
+0.24 (Strong)
MACD: 0.18 Signal: -0.06
Long-Term
+0.19 (Strong)
MACD: -0.07 Signal: -0.26
Intraday trend score
61.46
LOW49.46HIGH61.46
Latest news
OCS•12 articles•Positive: 11Neutral: 1Negative: 0
PositiveGlobeNewswire Inc.• Na
Oculis to Participate in Upcoming Investor Conferences
Oculis Holding AG announced participation in upcoming investor conferences in April 2026, highlighting a landmark year with multiple pivotal readouts expected. Key milestones include OCS-01 Phase 3 topline results for diabetic macular edema in June 2026, Licaminlimab registrational trial results for dry eye disease in late 2026, and Privosegtor receiving both FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis treatment. The company expects to deliver 6 pivotal readouts with current funding.
OCSOCSAWbiopharmaceuticalophthalmic diseasesclinical trialsFDA Breakthrough TherapyEMA PRIME designationdiabetic macular edema
Sentiment note
The company announced significant regulatory achievements (FDA Breakthrough Therapy and EMA PRIME designations for Privosegtor), multiple pivotal trial readouts expected in 2026, a strong balance sheet, and a robust late-stage pipeline with potential market opportunities exceeding $7B. These developments indicate strong progress and positive momentum in the company's transformation into a neuro-ophthalmology leader.
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis announced that its neuroprotective candidate Privosegtor has received Priority Medicines (PRIME) designation from the European Medicines Agency for treating optic neuritis. This follows the FDA's Breakthrough Therapy designation in January 2026. The designation is supported by positive Phase 2 ACUITY trial data showing improvements in vision and neuroprotective benefits. Oculis is advancing the PIONEER registrational program with trials in optic neuropathies.
The company received significant regulatory recognition with EMA PRIME designation and prior FDA Breakthrough Therapy designation for Privosegtor. Positive Phase 2 trial data, orphan drug status, and advancement into registrational trials represent substantial progress in drug development. The $7 billion potential market opportunity and accelerated regulatory pathways support positive momentum for the company's pipeline.
PositiveGlobeNewswire Inc.• Na
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis announced that its neuroprotective candidate Privosegtor received Priority Medicines (PRIME) designation from the European Medicines Agency for treating optic neuritis. This follows the FDA's Breakthrough Therapy designation in January 2026. The company is advancing the PIONEER registrational program with positive Phase 2 ACUITY trial data showing improvements in vision and neuroprotective benefits. Privosegtor has potential to become the first neuroprotective therapy for optic neuropathies, addressing a $7 billion market opportunity.
The company received significant regulatory recognition with EMA PRIME designation and FDA Breakthrough Therapy designation for Privosegtor, indicating strong clinical potential. Positive Phase 2 trial data, orphan drug status, and advancement into registrational trials demonstrate substantial progress. The $7 billion market opportunity and potential for first-in-class neuroprotective therapy represent significant commercial upside.
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis announced the presentation of Phase 2 ACUITY trial results for Privosegtor, a neuroprotective therapy for optic neuritis, at the North American Neuro-Ophthalmology Society's 52nd Annual Meeting on March 23, 2026. The trial demonstrated improved low-contrast visual acuity and reduction in retinal ganglion cell loss. Privosegtor has received FDA Breakthrough Therapy designation and the company is advancing the PIONEER registrational program, with PIONEER-1 trial initiated in Q4 2025.
OCSOCSAWPrivosegtoroptic neuritisPhase 2 ACUITY trialneuroprotective therapyNANOS 2026PIONEER program
Sentiment note
The company announced positive Phase 2 clinical trial results for its lead candidate Privosegtor, demonstrating efficacy in improving visual acuity and neuroprotection. The drug has received FDA Breakthrough Therapy designation, and the company is progressing to registrational trials, representing significant clinical and regulatory advancement.
PositiveGlobeNewswire Inc.• Na
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis announced the presentation of Phase 2 ACUITY trial results for Privosegtor, a neuroprotective therapy for optic neuritis, at the North American Neuro-Ophthalmology Society's 52nd Annual Meeting in Boston on March 23, 2026. The trial demonstrated improved low-contrast visual acuity and reduction in retinal ganglion cell loss. Privosegtor has received FDA Breakthrough Therapy designation and is advancing into the PIONEER registrational program, with the PIONEER-1 trial initiated in Q4 2025.
Positive Phase 2 trial results showing meaningful clinical improvements in visual acuity and neuroprotective effects; FDA Breakthrough Therapy designation; advancement to registrational trials; company positioned as potential first-to-market neuroprotective therapy for optic neuritis with broad applicability in neuro-ophthalmic diseases.
Oculis Holding AG has filed its audited consolidated financial statements for 2025 with the SEC on Form 20-F, following a March 3 press release. The company also announced its participation in upcoming investor conferences.
The article reports routine corporate actions (SEC filing of audited financial statements and investor conference participation) without disclosing specific financial results, performance metrics, or material developments. These are standard procedural announcements that do not indicate positive or negative business developments.
PositiveGlobeNewswire Inc.• Na
Oculis to Participate in Upcoming Investor Conferences
Oculis Holding AG announced its participation in three major investor conferences in March 2026. The company highlighted key pipeline milestones including Privosegtor's breakthrough therapy designation for optic neuritis, OCS-01's Phase 3 trial results expected in Q2 2026, and Licaminlimab's precision medicine approach for dry eye disease. With a strong balance sheet, Oculis expects to deliver 6 pivotal readouts with current funding.
The company announced multiple positive developments including breakthrough therapy designation for a lead candidate, on-track Phase 3 results, strong balance sheet, and planned delivery of 6 pivotal readouts. The announcement of investor conference participation and advancement of late-stage pipeline candidates demonstrates progress and confidence in the company's transformation into a neuro-ophthalmology leader.
PositiveGlobeNewswire Inc.• Na
Oculis to Participate in Upcoming Investor Conferences
Oculis Holding AG announced its participation in three major investor conferences in March 2026. The company highlighted key pipeline milestones including Privosegtor's breakthrough therapy designation for optic neuritis, OCS-01's Phase 3 trial results expected in Q2 2026, and Licaminlimab's precision medicine approach for dry eye disease. With a strong balance sheet, Oculis expects to deliver 6 pivotal readouts with current funding.
The company announced multiple positive developments including breakthrough therapy designation for a lead candidate, on-track Phase 3 results, strong balance sheet, and planned delivery of 6 pivotal readouts. The announcement of investor conference participation and advancement of late-stage pipeline candidates demonstrates progress and confidence in the company's transformation into a neuro-ophthalmology leader.
PositiveGlobeNewswire Inc.• Na
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG announced the appointment of Katie Kazem as Chief Legal Officer, bringing over 15 years of experience in life sciences corporate and securities law. The appointment comes as the company advances three late-stage clinical assets, including Privosegtor in registrational trials and OCS-01 eye drops with Phase 3 results expected in Q2 2026.
The appointment of an experienced CLO with strong track record in life sciences strengthens corporate governance and legal capabilities. The company is advancing multiple late-stage assets toward important clinical and regulatory milestones, demonstrating operational momentum and progress in its pipeline development.
PositiveGlobeNewswire Inc.• Not Specified
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG announced the appointment of Katie Kazem as Chief Legal Officer, bringing over 15 years of experience in life sciences corporate and securities law. The appointment comes as the company advances three late-stage clinical assets, including Privosegtor in registrational trials and OCS-01 eye drops with Phase 3 results expected in Q2 2026.
The appointment of an experienced CLO with 15+ years in life sciences law strengthens corporate governance and regulatory capabilities. The company is advancing three differentiated late-stage assets toward important clinical milestones, with Phase 3 results expected in Q2 2026, demonstrating significant momentum in its pipeline development.
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis presented positive Phase 2 trial results for Privosegtor, showing improved visual acuity and preservation of retinal ganglion cells in acute optic neuritis patients at the ECTRIMS 2025 Congress.
Company reported promising clinical trial results demonstrating potential breakthrough in treating optic neuritis, with significant improvements in visual function and neuroprotection
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis presented positive Phase 2 trial results for Privosegtor, a potential neuroprotective treatment for acute optic neuritis, showing improved visual acuity and preservation of retinal ganglion cells at the ECTRIMS 2025 Congress.
Company reported promising clinical trial results demonstrating potential breakthrough in treating optic neuritis, with significant improvements in visual function and a favorable safety profile
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
